Abstract
Our objective was to evaluate amyloid deposition in posterior cortical atrophy (PCA), using both cerebrospinal fluid (CSF) biomarker analysis and amyloid imaging. Five PCA patients, selected based on their neuropsychological profile and atrophic changes in posterior regions on MRI, underwent CSF analysis. CSF amyloid-beta 1–42, total tau, and phosphorylated tau at threonine 181 levels were determined. They also had positron emission tomography (PET) with Pittsburgh Compound B ([11C]PIB). [11C]PIB ratio images were assessed with visual, regional and voxel-based analyses and compared to eight typical Alzheimer's disease (AD) patients and eight controls. The biological profile in the five PCA patients, resulting from CSF and [11C]PIB images analysis, was consistent with AD. Individual comparisons of PCA patients’ [11C]PIB images with the AD group with Statistical Parametric Mapping (SPM) revealed a distinctive posterior uptake in four out of the five patients showing increased amyloid deposition in occipital, temporal, and/or parietal regions. ROI group analysis showed a tendency for higher amyloid deposition in occipital and temporal regions. However, this pattern was not found with SPM group analysis when the global level of [11C]PIB uptake was used as a covariate. Our results indicate that amyloid burden can be demonstrated in vivo in PCA suggesting a diagnosis of AD. PCA patients may present a higher global amyloid load than AD that was not related to age at onset, disease severity, disease duration, or educational level in our study. Combined CSF and PET biomarkers seem helpful for in vivo diagnosis of this focal syndrome with underlying AD pathology.
Similar content being viewed by others
References
Benson DF, Davis RJ, Snyder BD (1988) Posterior cortical atrophy. Arch Neurol 45(7):789–793
Tang-Wai DF et al (2004) Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 63(7):1168–1174
Renner JA et al (2004) Progressive posterior cortical dysfunction: a clinicopathologic series. Neurology 63(7):1175–1180
McMonagle P et al (2006) The cognitive profile of posterior cortical atrophy. Neurology 66(3):331–338
Formaglio M et al (2009) Homonymous hemianopia and posterior cortical atrophy. Rev Neurol (Paris) 165(3):256–62
Whitwell JL et al (2007) Imaging correlates of posterior cortical atrophy. Neurobiol Aging 28(7):1051–1061
Nestor PJ et al (2003) The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer’s disease) with FDG-PET. J Neurol Neurosurg Psychiatry 74(11):1521–1529
Schmidtke K, Hull M, Talazko J (2005) Posterior cortical atrophy: variant of Alzheimer’s disease? A case series with PET findings. J Neurol 252(1):27–35
Alladi S et al (2007) Focal cortical presentations of Alzheimer’s disease. Brain 130(Pt 10):2636–2645
Hof PR et al (1997) Atypical form of Alzheimer’s disease with prominent posterior cortical atrophy: a review of lesion distribution and circuit disconnection in cortical visual pathways. Vision Res 37(24):3609–3625
Hulstaert F et al (1999) Improved discrimination of AD patients using beta-amyloid(1–42) and tau levels in CSF. Neurology 52(8):1555–1562
Shaw LM et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 65(4):403–413
Mathis CA et al (2002) A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 12(3):295–298
Klunk WE et al (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 55(3):306–319
Engler H et al (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 129(Pt 11):2856–2866
Bacskai BJ et al (2007) Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 64(3):431–434
Lockhart A et al (2007) PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 130(Pt 10):2607–2615
Ikonomovic MD et al (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 131(Pt 6):1630–1645
Folstein MFFS, McHugh PR (1975) Mini-mental state. A pratical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198
Morris JC (1993) The clinical dementia rating (CDR): current version and scoring rules. Neurology 43(11):2412–2414
McKhann G et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34(7):939–944
Grober E, Buschke H (1987) Genuine memory deficits in dementia. Dev Psychol 3:13–36
Delis D et al (1987) The California Verbal Learning Test (research Ždition). Psychological corporation, New York
Cardebat DDB, Puel M, Goulet P, Joanette Y (1990) Formal and semantic lexial evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg 90:207–217
Bachy-Langedock N (1989) Batterie d’examen des troubles en denomination, Editest, Bruxelles
Stroop (1935) Studies of interferences in serial verbal reactions. J Exp Psychol 18:643–662
Reitan RM, Wolfson D (2004) The Trail Making Test as an initial screening procedure for neuropsychological impairment in older children. Arch Clin Neuropsychol 19(2):281–288
Rapport LJ, Millis SR, Bonello PJ (1998) Validation of the Warrington theory of visual processing and the visual object and space perception battery. J Clin Exp Neuropsychol 20(2):211–220
Sunderland T et al (1989) Clock drawing in Alzheimer’s disease. A novel measure of dementia severity. J Am Geriatr Soc 37(8):725–729
Hansson O et al (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5(3):228–234
Tapiola T et al (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66(3):382–389
Mattsson N et al (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. Jama 302(4):385–393
Lopresti BJ et al (2005) Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 46(12):1959–1972
Hammers A et al (2003) Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 19(4):224–247
Ashburner J, Friston KJ (2005) Unified segmentation. Neuroimage 26(3):839–851
Kambe T et al (2010) Posterior cortical atrophy with [11C] Pittsburgh compound B accumulation in the primary visual cortex. J Neurol 257(3):469–71
Migliaccio R et al (2009) Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology 73(19):1571–1578
Tenovuo O et al (2008) Posterior cortical atrophy: a rare form of dementia with in vivo evidence of amyloid-beta accumulation. J Alzheimers Dis 15(3):351–355
Ng SY et al (2007) Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. Arch Neurol 64(8):1140–1144
Grimmer T et al (2009) Clinical severity of Alzheimer’s disease is associated with PIB uptake in PET. Neurobiol Aging 30(12):1902–1909
Edison P et al (2007) Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 68(7):501–508
Kemppainen NM et al (2007) PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68(19):1603–1606
Rabinovici GD et al (2010) Increased metabolic vulnerability in early-onset Alzheimer’s disease is not related to amyloid burden. Brain 133(Pt 2): p 512–28
Forsberg A et al (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29(10):1456–1465
Gomperts SN et al (2008) Imaging amyloid deposition in Lewy body diseases. Neurology 71(12):903–910
Edison P et al (2008) Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79(12):1331–1338
Pike KE et al (2007) Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain 130(Pt 11):2837–2844
Villemagne VL et al (2008) Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer’s disease. Neuropsychologia 46(6):1688–1697
Baumann TP et al (2010) CSF-Tau and CSF-Abeta(1–42) in posterior cortical atrophy. Dement Geriatr Cogn Disord 29(6):530–533
Strozyk D et al (2003) CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60(4):652–656
Roher AE et al (2009) Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer’s disease. Biomarkers 14(7):493–501
Koopman K et al (2009) Improved discrimination of autopsy-confirmed Alzheimer’s disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem Int 55(4):214–218
Mulder C et al (2010) Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56(2):248–53
Hort J et al (2010) Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur J Neurol 17(1):90–6
Engelborghs S et al (2008) Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29(8):1143–1159
Iqbal K et al (2005) Subgroups of Alzheimer’s disease based on cerebrospinal fluid molecular markers. Ann Neurol 58(5):748–757
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Formaglio, M., Costes, N., Seguin, J. et al. In vivo demonstration of amyloid burden in posterior cortical atrophy: a case series with PET and CSF findings. J Neurol 258, 1841–1851 (2011). https://doi.org/10.1007/s00415-011-6030-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-011-6030-0